302 related articles for article (PubMed ID: 20736294)
1. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.
Rossi F; Yozgat Y; de Stanchina E; Veach D; Clarkson B; Manova K; Giancotti FG; Antonescu CR; Besmer P
Mol Cancer Res; 2010 Sep; 8(9):1271-83. PubMed ID: 20736294
[TBL] [Abstract][Full Text] [Related]
2. Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.
Bosbach B; Deshpande S; Rossi F; Shieh JH; Sommer G; de Stanchina E; Veach DR; Scandura JM; Manova-Todorova K; Moore MA; Antonescu CR; Besmer P
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):E2276-83. PubMed ID: 22652566
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
4. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
[TBL] [Abstract][Full Text] [Related]
5. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
Edris B; Willingham SB; Weiskopf K; Volkmer AK; Volkmer JP; Mühlenberg T; Montgomery KD; Contreras-Trujillo H; Czechowicz A; Fletcher JA; West RB; Weissman IL; van de Rijn M
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3501-6. PubMed ID: 23382202
[TBL] [Abstract][Full Text] [Related]
6. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
[TBL] [Abstract][Full Text] [Related]
7. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
Mahadevan D; Cooke L; Riley C; Swart R; Simons B; Della Croce K; Wisner L; Iorio M; Shakalya K; Garewal H; Nagle R; Bearss D
Oncogene; 2007 Jun; 26(27):3909-19. PubMed ID: 17325667
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells.
Dong Y; Liang C; Zhang B; Ma J; He X; Chen S; Zhang X; Chen W
Cancer Lett; 2015 May; 361(1):137-46. PubMed ID: 25737303
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
12. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
Kim TS; Cavnar MJ; Cohen NA; Sorenson EC; Greer JB; Seifert AM; Crawley MH; Green BL; Popow R; Pillarsetty N; Veach DR; Ku AT; Rossi F; Besmer P; Antonescu CR; Zeng S; Dematteo RP
Clin Cancer Res; 2014 May; 20(9):2350-62. PubMed ID: 24583793
[TBL] [Abstract][Full Text] [Related]
13. C-kit, GIST, and imatinib.
Siehl J; Thiel E
Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
[TBL] [Abstract][Full Text] [Related]
14. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Guo T; Agaram NP; Wong GC; Hom G; D'Adamo D; Maki RG; Schwartz GK; Veach D; Clarkson BD; Singer S; DeMatteo RP; Besmer P; Antonescu CR
Clin Cancer Res; 2007 Aug; 13(16):4874-81. PubMed ID: 17699867
[TBL] [Abstract][Full Text] [Related]
16. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.
Quattrone A; Wozniak A; Dewaele B; Floris G; Vanspauwen V; Van Looy T; Schöffski P; Rutkowski P; Sciot R; Debiec-Rychter M
Mod Pathol; 2014 Nov; 27(11):1510-20. PubMed ID: 24743220
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.
Rossi F; Ehlers I; Agosti V; Socci ND; Viale A; Sommer G; Yozgat Y; Manova K; Antonescu CR; Besmer P
Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12843-8. PubMed ID: 16908864
[TBL] [Abstract][Full Text] [Related]
18. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
19. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
Demetri GD
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
Sakurama K; Noma K; Takaoka M; Tomono Y; Watanabe N; Hatakeyama S; Ohmori O; Hirota S; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Tanaka N; Naomoto Y
Mol Cancer Ther; 2009 Jan; 8(1):127-34. PubMed ID: 19139121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
